Series B

With a new CFO and a massive infusion of public and private cash, Multibeam is scaling up. Here’s how its unique tech is becoming a cornerstone of the US CHIPS Act.

Meduloc's $4M Series B, led by GenHenn Capital and backed by Andre Ethier, fuels the launch of its innovative nitinol implant for better fracture healing.

With $350M+ in funding, Acrab is challenging cloud giants with custom silicon for powerful local AI. This is their strategy to own the agentic AI future.

Expedition Therapeutics lands a huge Series B and starts a pivotal trial for a drug that could finally target the root cause of COPD for millions.

With a fresh $37M, WindBorne Systems is scaling its fleet of AI-guided balloons to create a new intelligence layer for our weather-dependent world.

With a strategic investment from UMass Memorial Health, Wellinks is scaling its predictive tech to prevent crises before they start. A new model for chronic care.

With $100M in total funding, bioinformatics firm Inocras plans to challenge U.S. precision oncology leaders by leveraging its whole-genome sequencing success in Asia.

South Korean robotic hand specialist Tesollo targets a post-2027 IPO, fueled by strategic Series B funding and a mission to dominate industrial automation.

With a massive $113M Series B, Onyx Security is tackling enterprise AI's biggest risk: unaccountable agents. It's a bet on a new security category.

With backing from Galaxy, Coinbase, and Franklin Templeton, Soter Insure is building the risk management infrastructure that could finally bring Wall Street to crypto.

With $26M in new funding, Epitel is scaling its wireless, AI-powered EEG system, aiming to revolutionize seizure diagnosis and bridge a critical care gap.

Palo Alto's Atropos Health just published 12 studies in six months using AI, revealing insights on everything from GLP-1s to Crohn's. It's a new paradigm for medicine.

With an oversubscribed $130M Series B, Crystalys Therapeutics is accelerating its gout drug, dotinurad. But can it win the race to serve millions?

Hilo launches its wearable blood pressure system in the U.S., trading the old cuff for continuous data. Is this the future of heart health or a pricey wellness gadget?

With a fresh $55M led by Khosla Ventures, Bunkerhill Health is deploying agentic AI to bridge healthcare's operational gaps and save lives. Here's why.

With a fresh $150M, Mighty Therapeutics is set to expand its groundbreaking mitochondrial drugs from rare diseases to major conditions like Parkinson's.

A new partnership between AI platform Agentio and Meta promises to automate creator advertising, swapping manual deals for data-driven performance.

MindRank's AI platform propelled a GLP-1 drug to Phase III in record time. Its new $52M funding aims to prove this isn't a one-off, but a revolution.

With a multi-million-dollar Series B, Kuehnle AgroSystems is commercializing a novel tech that promises to upend the $2B natural astaxanthin market.

As AI moves from training to production, a new infrastructure battle begins. DeepInfra's Canadian expansion reveals the race for low-latency, global inference.